Quick Answer
Outlook Therapeutics, Inc. reported Operating Income of -$67.06 million for fiscal year 2025.
Outlook Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$67.06M | +6.5% |
| 2024 | -$71.70M | -35.0% |
| 2023 | -$53.13M | +15.8% |
| 2022 | -$63.07M | -21.9% |
| 2021 | -$51.73M | -40.4% |
| 2020 | -$36.84M | -1.5% |
| 2019 | -$36.30M | -22.4% |
| 2018 | -$29.64M | +17.4% |
| 2017 | -$35.88M | +30.1% |
| 2016 | -$51.35M | -10.3% |
| 2015 | -$46.56M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$13.48M | +37.6% | +14.4% |
| June 30, 2025 | -$15.75M | +19.5% | -27.1% |
| March 31, 2025 | -$12.39M | +34.6% | +42.7% |
| December 31, 2024 | -$21.61M | -109.3% | -10.4% |
| June 30, 2024 | -$19.56M | -7.8% | -3.3% |
| March 31, 2024 | -$18.94M | -177.0% | -83.5% |
| December 31, 2023 | -$10.32M | +34.2% | +43.1% |
| June 30, 2023 | -$18.14M | -6.6% | -165.3% |
- Outlook Therapeutics, Inc. showed an increase of +6.5% in Operating Income compared to the prior fiscal year.
- Over the 2015–2025 period, Outlook Therapeutics, Inc.’s operating income has declined by 44.0% (from -$46.56 million to -$67.06 million).
- The most recent figure is from Outlook Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 19, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: